Related Experiment Video
Updated: Jul 14, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
[Experimental study on treating hyperlipidemic fatty liver with Taizhi'an capsule]
Mei Sun1, Jian-Zhen Shan, Guo-Ping Zhang
1Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou 310009, China.
Taizhi'an capsule effectively treats hyperlipidemic fatty liver in rats by improving liver function and lipid profiles. This traditional Chinese medicine demonstrates significant therapeutic potential for managing this condition.
Area of Science:
- Pharmacology
- Hepatology
- Traditional Chinese Medicine
Context:
- Hyperlipidemic fatty liver is a growing health concern.
- Current treatments have limitations.
- Taizhi'an capsule is a traditional Chinese medicine preparation.
Purpose:
- To evaluate the efficacy of Taizhi'an capsule in a rat model of hyperlipidemic fatty liver.
- To assess the impact of Taizhi'an capsule on liver function, blood lipids, and liver histology.
Summary:
- High-caloric diet induced hyperlipidemic fatty liver in rats, characterized by elevated liver index, blood lipids, liver lipids, liver enzymes, and decreased SOD.
- Treatment with Taizhi'an capsule (high and middle doses) significantly reduced liver index, blood lipids, liver lipids, and liver enzymes.
- Taizhi'an capsule treatment also increased SOD levels and improved liver histology, normalizing liver function and reducing fat denaturation.
Impact:
- Taizhi'an capsule shows significant therapeutic potential for hyperlipidemic fatty liver.
- This study provides evidence for the use of Taizhi'an capsule in managing metabolic liver diseases.
- Further research may explore its mechanisms of action and clinical applications.
More Related Videos
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
07:03In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents